Gram-Negative Bacterial Infections clinical trials

The registry lists 58 studies for Gram-Negative Bacterial Infections across more than 10 countries. 10 are recruiting or about to start. 36 of them are mainly about Gram-Negative Bacterial Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-29. Counting its 22 narrower conditions too, such as Whooping Cough: 1,784 studies, 255 open.

Get an email when these change. Save the Gram-Negative Bacterial Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 35
Recruiting: 8
Status unknown: 5
Terminated: 4
Withdrawn: 2
Not yet recruiting: 2

Phase

Phase 2: 13
Phase 4: 10
Phase 3: 8
Phase 1: 7

Where

United States: 23
Greece: 9
Italy: 7
China: 6
Spain: 6
Taiwan: 5

Who runs them

Pfizer (4) · University of Pittsburgh (3) · Shionogi (3) · Merck Sharp & Dohme LLC (2) · GlaxoSmithKline (2) · Methodist Health System (2) · PATH (2) · Wake Forest University Health Sciences (1)

What is being tested here

Drugs under test in Gram-Negative Bacterial Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Cefiderocol	1	0	4
Aztreonam	1	0	1
Heparin	1	1	1
Imipenem	0	0	2
HRS-8427	0	0	1
Clarithromycin	0	1	1
Colistinmethanesulfonic acid	0	0	1
Epetraborole	0	0	1
Hiberix	0	1	1
Pediarix	0	1	1

Drug classes tested here Beta-lactamase inhibitors 1 open

Coming up

3phase 3 studies under way

5studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 5

Feb 2027Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries · University of Tennessee
Mar 2027Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections · Pfizer
Apr 2027A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH) · Pfizer
Jul 2027Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients · Sizhou Feng
Oct 2027A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure · Tarsus Pharmaceuticals, Inc.

Who these studies take

Of the 8 Gram-Negative Bacterial Infections studies recruiting now, 2 (25%) set no upper age limit and 4 (50%) stop at 75 or younger. 2 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (13%) take healthy volunteers.

Recruiting studies that take each age, of 8
Age	Women	Men
10	1 (13%)	1 (13%)
18	5 (63%)	5 (63%)
30	6 (75%)	6 (75%)
40	6 (75%)	6 (75%)
50	6 (75%)	6 (75%)
65	5 (63%)	5 (63%)
75	5 (63%)	5 (63%)
85	3 (38%)	3 (38%)

Across all 58 studies, recruiting or not: 43% stop at 75 or younger and 34% at 65; 28% take children; 0% are for women only and 2% for men only; 22% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 50 of 58. Browse all 58 → or search them.